Ro60-0213 (Org 35032) is a drug developed by Hoffmann–La Roche, which acts as a potent and selective agonist for the 5-HT2C serotonin receptor, with more than 100x selectivity over other closely related serotonin receptor subtypes, and little or no affinity at other receptors. It was developed as a potential antidepressant,[1] but was discontinued from clinical development at an early stage due to toxicity concerns.[2] However the high selectivity of Ro60-0213 for 5-HT2C makes it of continued interest for research into serotonin receptors.[3]
See also
- 5-MeO-AMT
- AL-34662
- AL-38022A
- Ro60-0175
- VER-3323
- YM-348
References
- Trends in Drug Research II, Proceedings of the 11th Noordwijkerhout-Camerino Symposium 1998^
- Suppression of mutagenic activity of a series of 5HT2c receptor agonists by the incorporation of a gem-dimethyl group: SAR using the Ames test and a DNA unwinding assay Mutagenesis, July 1998^
- Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists Bioorganic & Medicinal Chemistry, February 2008^